Hikma Pharma GmbH Sustainability Profile
Hikma Pharma GmbH, a prominent player in the pharmaceutical industry, is headquartered in Germany and operates extensively across Europe and beyond. Founded in 1978, the company has established itself as a leader in the development and manufacturing of generic and branded medications, focusing on high-quality, affordable healthcare solutions. With a diverse portfolio that includes injectable medications, oral solids, and complex generics, Hikma Pharma is renowned for its commitment to innovation and quality. The company’s state-of-the-art facilities and rigorous quality control processes ensure that its products meet the highest industry standards. Hikma Pharma GmbH has achieved significant milestones, positioning itself as a trusted partner in the healthcare sector, dedicated to improving patient outcomes through accessible medication. Its strategic focus on research and development continues to drive its success in a competitive market.
DitchCarbon Score
How does Hikma Pharma GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hikma Pharma GmbH's score of 58 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hikma Pharma GmbH, headquartered in Germany, currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is a current subsidiary of Hikma Pharmaceuticals PLC, which may influence its climate commitments and reporting practices. While there are no documented reduction targets or specific climate pledges from Hikma Pharma GmbH, emissions data and performance metrics are inherited from its parent company, Hikma Pharmaceuticals PLC. This relationship may provide a framework for future climate initiatives and emissions reporting. As part of the broader pharmaceutical industry, Hikma Pharma GmbH is expected to align with emerging sustainability practices and may adopt targets in line with industry standards. However, without specific data or commitments, the company's current climate impact remains unclear.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 16,817,000 | - | - | 00,000,000 | 00,000,000 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 49,779,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
How Carbon Intensive is Hikma Pharma GmbH's Industry?
How Carbon Intensive is Hikma Pharma GmbH's Location?
Hikma Pharma GmbH's Scope 3 Categories Breakdown
Hikma Pharma GmbH's Scope 3 emissions, which decreased by 95% last year and decreased by approximately 94% since 2021, demonstrating supply chain emissions tracking. Their carbon footprint includes suppliers and value chain emissions, with Scope 3 emissions accounting for 26% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 1599% of Scope 3 emissions.
Top Scope 3 Categories
Hikma Pharma GmbH's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Hikma Pharma GmbH has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
